NASDAQ:LIVN - Nasdaq - GB00BYMT0J19 - Common Stock - Currency: USD
36.78
-0.01 (-0.03%)
The current stock price of LIVN is 36.78 USD. In the past month the price decreased by -1.87%. In the past year, price decreased by -42.67%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.79 | 230.35B | ||
ISRG | INTUITIVE SURGICAL INC | 69.3 | 189.75B | ||
BSX | BOSTON SCIENTIFIC CORP | 38.86 | 155.20B | ||
SYK | STRYKER CORP | 30.19 | 144.36B | ||
MDT | MEDTRONIC PLC | 15.89 | 108.82B | ||
BDX | BECTON DICKINSON AND CO | 11.98 | 48.46B | ||
EW | EDWARDS LIFESCIENCES CORP | 29.1 | 44.47B | ||
IDXX | IDEXX LABORATORIES INC | 41.39 | 38.24B | ||
RMD | RESMED INC | 26.43 | 35.18B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.33 | 32.29B | ||
DXCM | DEXCOM INC | 49.47 | 32.00B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 16.2 | 24.05B |
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. The firm designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the design, development, manufacture, marketing and selling of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula and other related accessories. The company includes the Essenz Perfusion System, the Company’s next-generation HLM with an embedded patient monitor for tailored patient care strategies. Neuromodulation segment is engaged in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). The ACS segment is engaged in the development, production, and sale of temporary life support products.
LIVANOVA PLC
20 Eastbourne Terrace
London W2 6LG GB
CEO: Damien McDonald
Employees: 2900
Phone: 442033250662
The current stock price of LIVN is 36.78 USD. The price decreased by -0.03% in the last trading session.
The exchange symbol of LIVANOVA PLC is LIVN and it is listed on the Nasdaq exchange.
LIVN stock is listed on the Nasdaq exchange.
16 analysts have analysed LIVN and the average price target is 61.88 USD. This implies a price increase of 68.24% is expected in the next year compared to the current price of 36.78. Check the LIVANOVA PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
LIVANOVA PLC (LIVN) has a market capitalization of 2.00B USD. This makes LIVN a Small Cap stock.
LIVANOVA PLC (LIVN) currently has 2900 employees.
LIVANOVA PLC (LIVN) has a support level at 33.95 and a resistance level at 36.87. Check the full technical report for a detailed analysis of LIVN support and resistance levels.
The Revenue of LIVANOVA PLC (LIVN) is expected to grow by 4.33% in the next year. Check the estimates tab for more information on the LIVN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
LIVN does not pay a dividend.
LIVANOVA PLC (LIVN) will report earnings on 2025-05-07, before the market open.
The PE ratio for LIVANOVA PLC (LIVN) is 10.91. This is based on the reported non-GAAP earnings per share of 3.37 and the current share price of 36.78 USD. Check the full fundamental report for a full analysis of the valuation metrics for LIVN.
The outstanding short interest for LIVANOVA PLC (LIVN) is 3.03% of its float. Check the ownership tab for more information on the LIVN short interest.
ChartMill assigns a fundamental rating of 5 / 10 to LIVN. Both the profitability and the financial health of LIVN get a neutral evaluation. Nothing too spectacular is happening here.
Over the last trailing twelve months LIVN reported a non-GAAP Earnings per Share(EPS) of 3.37. The EPS increased by 19.93% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 5.04% | ||
ROA | 2.52% | ||
ROE | 4.79% | ||
Debt/Equity | 0.42 |
ChartMill assigns a Buy % Consensus number of 81% to LIVN. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of 7.69% and a revenue growth 4.33% for LIVN